Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.
Susan Mary O'Brien
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Jacqueline Claudia Barrientos
Research Funding - Pharmacyclics
Ian W. Flinn
No relevant relationships to disclose
Paul M. Barr
No relevant relationships to disclose
Jan Andreas Burger
Consultant or Advisory Role - Pharmacyclics
Tasheda Navarro
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Eric Hedrick
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Jonathan W. Friedberg
No relevant relationships to disclose
Jennifer R. Brown
Consultant or Advisory Role - Avila Therapeutics; Novartis; Pharmacyclics
Research Funding - Celgene; Genzyme